Pharmaceutical industry will usher in the golden years of the recommended 9 to 10 times 10 shares (list)

 Pharmaceutical industry will usher in the golden years of the recommended 9 to 10 times 10 shares (list)
2007   12   11   08:30:07
cities in the pharmaceutical sector financial network performance eye-catching today, or among all sectors index in the forefront.
Medicines shares (600,511) shares of the leading pharmaceutical filling style, was also among the biggest gainers, Topsun Science and Technology (600771) rose 8.19%, reported 15.58 yuan; Guangji Pharmaceutical (000952) rose 8% reported 28.61 yuan; same medicine rose 5% of the reported 19.30 yuan.
some analysts pointed out that for health care reform to stimulate domestic demand and good expectations, the pharmaceutical industry will usher in a golden period of development. Recently the disk from a situation, medical share capital has become a focus of Jiancang, I believe the future will have better performance for some time.
pharmaceutical industry: rapid recovery from the winter in 10 years to buy 10 times the bull stock (source: National League securities)
2007 年operation of the pharmaceutical industry is China's pharmaceutical industry sales revenue totaled 416.27 billion yuan, up 26.64% over last year, the accumulated total profit of 37.365 billion yuan over last year by rolling 49.74%.
stock has experienced since the reform of the pharmaceutical industry from the wind and rain in the regeneration process, regression in the realization of the value of the process, has gradually moved toward the overvaluation, either earnings or net profit increased levels are close to the ceiling, it is difficult to re-than-expected results from the valuation and promotion of pharmaceutical listed on the company's share price rose . Second, listed companies from abroad, the development of pharmaceutical industry experience point of view: income : , and have certain core competencies to ensure that the industry will not experience in the development process a great challenge, and to maintain long-term stability and even growth.
Our choice is:
biopharmaceutical: Temple of Heaven biology, medicine and science and Chinese double-Heron Bio.
pharmaceutical distribution companies: Sinopharm shares, Guangzhou Pharmaceutical, and Huadong Medicine.
Chinese: Hong Mei medicine, the river edge of medicine and health medicine.
Our idea is: When the pharmaceutical industry started to recover from 2007, and fully understanding the market after a year after the valuation, or both are close to the ceiling of earnings growth, it is difficult then-expected results from the valuation and up to promote the pharmaceutical companies rose. Second, the pharmaceutical industry from foreign experience, we listed the company's development: pharmaceutical companies to share best long-term growth and income.